Project name: Innitius
EU Contribution: € 3 800 000
Location: Spain
Innitius develops CerviSense, a CE-marked diagnostic platform that measures cervical stiffness using torsional wave elastography and AI. It allows clinicians to detect risk of preterm labor, failed inductions, and false labor earlier and more accurately. By reducing diagnostic uncertainty, it improves outcomes for mothers and babies, prevents unnecessary interventions, and brings advanced, accessible maternal care to both high-resource and underserved health systems.
Vision & ImpactCerviSense is transforming maternal health by offering the first objective, biomechanical method to detect risk in pregnancy. By reducing diagnostic uncertainty, it helps prevent preterm births, avoid unnecessary interventions, and bring equity to women’s care globally.
CollaborationThe EIC Accelerator has been a turning point in our journey. It enabled us to launch our pivotal clinical trials, scale production, and unlock cross-border partnerships. Beyond funding, it gave us trust, visibility, and a European platform to drive systemic change in obstetric care.
What's next ?We are expanding CerviSense across Europe with leading hospitals, launching pilots in Africa to address maternal health inequities, and initiating FDA steps for U.S. approval. Our next goal is to embed CerviSense as a standard tool in global pregnancy risk management.
The EIC support is helping us build a world where preterm birth no longer begins with guesswork. Thanks to this program, CerviSense is already in hospitals protecting mothers and babies. The EIC didn’t just fund innovation — it helped us reshape the clinical standard for safer pregnancies worldwide.